Residual risk for coronary heart disease events and mortality despite intensive medical management after myocardial infarction

High-intensity statins, beta-blockers, angiotensin-converting enzyme inhibitors, angiotensin receptor blockers, and antiplatelet agents (ie, intensive medical management) reduce coronary heart disease (CHD) risk after myocardial infarction (MI).
Source: Journal of Clinical Lipidology - Category: Lipidology Authors: Tags: Original Article Source Type: research

Related Links:

Abstract Atherosclerosis (AS) is the main pathological cause of coronary heart disease (CHD). Current clinical interventions including statin drugs can effectively reduce acute myocardial infarction and stroke to some extent, but residual risk remains high. The current clinical treatment regimens are relatively effective for early atherosclerotic plaques and can even reverse their progression. However, the effectiveness of these treatments for advanced AS is not ideal, and advanced atherosclerotic plaques-the pathological basis of residual risk-can still cause a recurrence of acute cardiovascular and cerebrovascul...
Source: Acta Pharmacologica Sinica - Category: Drugs & Pharmacology Authors: Tags: Acta Pharmacol Sin Source Type: research
Authors: Altunina NV, Lizogub VG, Bondarchuk OM Abstract Patients with combined coronary heart disease and diabetes mellitus make up a growing segment of the population and require a comprehensive treatment approach. Patients with concurrent diabetes mellitus and coronary heart disease have a worse projection. Under these conditions, the incidence of recurrent myocardial infarction, early disability due to complications, and the risk of coronary death are increased. Therefore, the priority task is to find ways to optimize drug treatment of this category of patients, taking into account the impact of drugs on the pa...
Source: Journal of Medicine and Life - Category: General Medicine Tags: J Med Life Source Type: research
CONCLUSION: Since there was no statistical significance between the probucol and control groups despite a marked reduction of HDL-C, further studies on the clinical outcomes of probucol on top of conventional therapy may be necessary in the future (UMIN000003307). PMID: 32336695 [PubMed - as supplied by publisher]
Source: Journal of Atherosclerosis and Thrombosis - Category: Cardiology Tags: J Atheroscler Thromb Source Type: research
In conclusion, the recently demonstrated protective effects of NMN treatment on neurovascular function can be attributed to multifaceted sirtuin-mediated anti-aging changes in the neurovascular transcriptome. Our present findings taken together with the results of recent studies using mitochondria-targeted interventions suggest that mitochondrial rejuvenation is a critical mechanism to restore neurovascular health and improve cerebral blood flow in aging. Wnt/β-Catenin Signaling as a Point of Intervention to Spur Greater Neural Regeneration https://www.fightaging.org/archives/2020/02/wnt-%ce%b2-catenin-sig...
Source: Fight Aging! - Category: Research Authors: Tags: Newsletters Source Type: blogs
The clinical work on lowering blood cholesterol that has taken place over recent years has demonstrated that if there is a lower limit beyond which low cholesterol levels become harmful, then that limit is very low indeed. Certainly below 10% of the normal human level. There are a number of uncommon mutations that produce individuals with up to half of the normal amount of blood cholesterol, people who exhibit significantly reduced risk of cardiovascular disease as a result of this difference from the norm. This is all quite interesting: why did we evolve to have the blood cholesterol that we do, if we need only a small fr...
Source: Fight Aging! - Category: Research Authors: Tags: Medicine, Biotech, Research Source Type: blogs
Authors: Alwi I Abstract Over more than two decades, the concept of atherosclerosis has developed and lead to inflammatory hypothesis. Inflammation plays an important role on pathogenesis of atherothrombosis and coronary heart disease (CHD), including acute coronary syndrome (ACS). Although the management of ACS has been demonstrated to be beneficial for secondary prevention of coronary heart disease (such as using statin and aspirin) and also seemed to have positive effect on inflammation, the identification of effective management, specifically targeting inflammation, has been not been comprehensively understood....
Source: Acta medica Indonesiana - Category: Internal Medicine Tags: Acta Med Indones Source Type: research
In this interview with Dr. Lee Hooper we find out more about this new Cochrane review -Omega-3 fatty acids for the primary and secondary prevention of cardiovascular diseaseTell us about this Cochrane ReviewThere is a great deal of public belief in the cardiovascular benefits of omega-3 fats.   Intakes of long-chain omega-3 fats in the US are higher from dietary supplements than foods.  But public health advice differs across countries. The National Institute for Health and Clinical Excellence in the UK encourages people to eat oily fish intake (the major source of long-chain omega-3 f ats) but discourages supple...
Source: Cochrane News and Events - Category: Information Technology Authors: Source Type: news
High-intensity statins, beta-blockers, angiotensin converting enzyme inhibitors, angiotensin receptor blockers, and antiplatelet agents (i.e. intensive medical management) reduce coronary heart disease (CHD) risk following myocardial infarction (MI).
Source: Journal of Clinical Lipidology - Category: Lipidology Authors: Tags: Original Research Source Type: research
AbstractPurpose of ReviewTo review randomized interventional clinical and imaging trials that support lower targeted atherogenic lipoprotein cholesterol goals in “extreme” and “very high” atherosclerotic cardiovascular disease (ASCVD) risk settings. Major atherosclerotic cardiovascular event (MACE) prevention among the highest risk patients with ASCVD requires aggressive management of global risks, including lowering of the fundamental atherogenic ap olipoprotein B-associated lipoprotein cholesterol particles [i.e., triglyceride-rich lipoprotein remnant cholesterol, low-density lipoprotein cholester...
Source: Current Diabetes Reports - Category: Endocrinology Source Type: research
Diagnoses increase but gender gap in treatment persist Related items fromOnMedica Coronary heart disease remains UK ’s biggest killer Glucosamine supplements may reduce stroke risk The new GP contract: transforming primary care, transforming CVD prevention Statins halve heart attack and stroke risk in healthy adults More Scottish GPs needed to fight heart disease
Source: OnMedica Latest News - Category: UK Health Source Type: news
More News: Beta-Blockers | Cardiology | Cholesterol | Coronary Heart Disease | Heart | Heart Attack | Heart Disease | Lipidology | Statin Therapy